Atherosclerosis in primary antiphospholipid syndrome.

Area of Science:

• Immunology
• Vascular Biology
• Rheumatology

Background:

• Antiphospholipid syndrome (APS) is a primary cause of acquired thrombophilia.
• Clinical manifestations of APS extend beyond hypercoagulability, suggesting broader vascular involvement.
• The role of antiphospholipid antibodies (aPLs) in atherosclerosis, particularly in primary APS, requires further elucidation.

Purpose of the Study:

• To investigate the contribution of antiphospholipid antibodies to premature atherosclerosis in primary APS.
• To determine the mechanisms by which aPLs impair vascular homeostasis.

Main Methods:

• Review of clinical and experimental evidence regarding APS and atherosclerosis.
• Analysis of data from primary APS patient cohorts.
• Assessment of the impact of aPLs on coagulation, vessel wall integrity, and oxidant/antioxidant balance.

Main Results:

• Traditional atherosclerosis risk factors appear less significant in primary APS arterial disease.
• Antiphospholipid antibodies are identified as major contributors to premature atherosclerosis in APS.
• aPLs disrupt vascular homeostasis through effects on coagulation, the vessel wall, and redox balance.

Conclusions:

• Antiphospholipid antibodies play a critical role in the pathogenesis of premature atherosclerosis in APS.
• The vascular complications of APS are mediated by aPLs' multifaceted impact on vascular health.
• Understanding these mechanisms is crucial for managing APS-associated arterial disease.